Jump to content

Indegene

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 2409:4062:219c:c47a:8c87:ac5a:86b8:4857 (talk) at 11:45, 6 May 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Indegene
FormerlyIndegene Lifesystems[1]
Company typePublic
Industry
Founded1998; 26 years ago (1998)
FoundersRajesh Nair
Manish Gupta
Sanjay Parikh
Anand Kiran
Gaurav Kapoor
Headquarters
Bangalore
,
India
Area served
Worldwide
Key people
Manish Gupta (CEO)[2]
RevenueIncrease ₹2,306 crore (US$280 million) (FY23)[3]
Increase ₹266 crore (US$32 million) (FY23)[3]
Owners
Number of employees
4,100 (2021)[4]
Websitewww.indegene.com

Indegene Limited is an Indian company that provides research and commercialization services to biopharmaceutical and healthcare enterprises.[5][6][7] Based in Bangalore, the company specializes in pharmaceutical marketing, clinical trials, pharmacovigilance, medical and regulatory affairs, and health informatics.[4][8]

History

Indegene was founded in 1998 by Dr. Rajesh Nair, Manish Gupta, Gaurav Kapoor, Dr.Sanjay Parikh and Anand Kiran.[9] Indegene's first acquisition was Medsn, a company that provided medical education. Medsn continued to operate under the same name in the United States.[10] In 2008, Medsn officially became known as Indegene Pharmaceutical Solutions in the United States. In 2006, Indegene acquired MedCases, a continuing medical education company based in the United States.[7][11]

In 2009, Indegene signed a master service agreement with six pharmaceutical companies.[6][12] The following year, Indegene acquired Canada-based Aptilon, a multichannel marketing firm, for $4 million.[13] The company subsequently acquired Atlanta-based Total Therapeutic Management in 2014.[14]

In September 2019, Indegene acquired London-based consulting company, DT Associates, for $10 million.[15]

In February 2021, the Carlyle Group and Brighton Park Capital invested $200 million in Indegene.[16] In August 2021, Indegene acquired Medical Marketing Economics (MME), an American market access and pricing strategy company, for $10 million.[17]

Indegene IPO opens for subscription on May 6, 2024 and closes on May 8, 2024.The IPO of the company has an issue size of Rs. 1841.76 crore. Further, the face value of its Equity Shares is Rs. 2. This IPO’s price range is between  ₹430 to ₹452. After it opens on 6th May 2024, it will remain open until 8th May 2024, (Monday to Wednesday this week). Indegene IPO will be listed on the Stock Exchanges BSE Limited and the National Stock Exchange of India Limited (NSE).[18]

Operations

Indegene has offices in India, the United States, the European Union, and Asia-Pacific.[19][11]

In 2011 and 2012, The Economic Times named Indegene one of the best companies to work for in the Professional Services industry.[20]

See also

References

  1. ^ Mendonca, Jochelle (28 November 2015). "Healthcare IT firm Indegene targets $250 million in revenue by 2020, looking at Nasdaq IPO". The Economic Times. Retrieved 28 April 2024.
  2. ^ "Indegene on the prowl for global acquisitions". The Hindu Businessline. 12 August 2020. Retrieved 8 January 2023.
  3. ^ a b c "PE firms Carlyle, Nadathur Fareast, Brighton Park Capital-backed Indegene IPO to open on May 6". Moneycontrol. Retrieved 28 April 2024.
  4. ^ a b Murayama, Keiichi (19 February 2015). "India's tech muscle has the world's attention". The Nikkei. Retrieved 2 October 2015.
  5. ^ Das, Avik (2 September 2015). "Flipkart, Practo CEOs get top rating from staff". The Economic Times. Retrieved 2 October 2015.
  6. ^ a b Singh, Seema (7 May 2009). "Cutting pharma costs by intelligent marketing". Mint. Retrieved 2 October 2015.
  7. ^ a b Unnikrishnan, CH (8 November 2006). "Indegene buys US firm". Business Standard. Retrieved 2 October 2015.
  8. ^ "Indegene files papers with Sebi; eyes ₹3,200 crore via IPO". mint. 15 December 2022. Retrieved 8 January 2023.
  9. ^ Amirapu, Deepika (9 March 2012). "Indegene eyes US call centre buy for $10–15 million". The Economic Times. Retrieved 2 October 2015.
  10. ^ D'Silva, Jeetha (17 September 2005). "Indegene acquires US medical education co". The Economic Times. Retrieved 2 October 2015.
  11. ^ a b "Indegene acquires MedCases, LLC". NFV Zone. 30 November 2006. Retrieved 2 October 2015.
  12. ^ "Indegene highlights benefits of patient adherence programs for pharma cos". PharmaBiz. 3 June 2011. Retrieved 2 October 2015.
  13. ^ Mukherjee, Rupali (7 November 2012). "Indegene to acquire Canada-based company for $4 million". Times of India. Retrieved 2 October 2015.
  14. ^ Craig, Tara (9 January 2014). "Indegene acquires Total Therapeutic Management". PMLive.com. Retrieved 2 October 2015.
  15. ^ Balakrishnan, Reghu (3 September 2019). "Healthcare tech firm Indegene acquires DT Associates". The Economic Times. Retrieved 28 April 2024.
  16. ^ Madhurima, Nandy (3 February 2021). "Indegene to raise $200 mn from Carlyle, Brighton Park". LiveMint. Retrieved 20 August 2021.
  17. ^ Baruah, Ayushman (30 August 2021). "Indegene acquires US-based Medical Marketing Economics for $10 mn". Mint. Retrieved 28 April 2024.
  18. ^ "Indegene Ltd IPO: Overview, Date, Price, GMP & Review". 6 May 2024. Retrieved 6 May 2024.
  19. ^ Vijay, Nandita (7 November 2012). "Indegene plans next phase of growth through acquisition in US, EU markets". PharmaBiz. Retrieved 2 October 2015.
  20. ^ "Best companies to work for 2012: Companies that came up trumps across various sectors". The Economic Times. 16 July 2012. Retrieved 2 October 2015.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Indegene&oldid=1222515112"